Risk-adjusted therapy for pediatric non-T cell ALL improves outcomes for standard risk patients: results of JACLS ALL-02.
Hasegawa D, Imamura T, Yumura-Yagi K, Takahashi Y, Usami I, Suenobu SI, Nishimura S, Suzuki N, Hashii Y, Deguchi T, Moriya-Saito A, Kato K, Kosaka Y, Hirayama M, Iguchi A, Kawasaki H, Hori H, Sato A, Kudoh T, Nakahata T, Oda M, Hara J, Horibe K; Japan Association of Childhood Leukemia Study Group (JACLS).
Hasegawa D, et al. Among authors: hara j.
Blood Cancer J. 2020 Feb 27;10(2):23. doi: 10.1038/s41408-020-0287-4.
Blood Cancer J. 2020.
PMID: 32107374
Free PMC article.
Clinical Trial.